AI-powered MRI radiomics significantly improves prediction of treatment response in advanced liver cancer patients.
Key Details
- 1Multicenter study presented at ASCO 2025 focused on advanced hepatocellular carcinoma (HCC).
- 2AI-based radiomics model analyzed MRI data to predict response to atezolizumab and bevacizumab therapy.
- 3Study included 240 patients; training cohort of 161, validation cohort of 79.
- 4Radiomics model achieved AUC of 0.913 (training) and 0.825 (validation); combined with a key MRI feature, AUC increased to 0.951 and 0.835, respectively.
- 5Significant correlation found between radiomic and conventional MRI features for intrahepatic lesions.
Why It Matters
This work demonstrates the power of AI-driven radiomics to personalize cancer treatment planning, improve patient selection for liver cancer therapies, and highlights growing integration of advanced imaging analytics in clinical oncology workflows.
Source
AuntMinnie
Related News
•AuntMinnie
AI Model Uses Ultrasound to Assess Fetal Lung Maturity
Researchers demonstrated an AI model's strong accuracy in measuring fetal lung maturity from ultrasound images.
•AuntMinnie
AI Model Predicts Dosimetry for Lu-177 PSMA Therapy Using PET/CT
A machine learning PET/CT model shows promise for predicting radiation dose prior to Lu-177 PSMA therapy in prostate cancer patients.
•AuntMinnie
AI Advances in Ultrasound Highlighted at AIUM 2026 Keynote
AI is increasingly enhancing ultrasound imaging, clinical workflows, and education, though challenges in trust and implementation remain.